Abstract
In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis factor α (TNFα), interleukin-1 (IL-1), vascular endothelial growth factor (VEGF), and fibroblast growth factors (FGFs). Receptor triggering initiates intracellular signal transduction leading to activation of nuclear factor κB (NFκB), mitogen activated protein kinase (MAPK) activity, and nitric oxide and reactive oxygen species production, among others. As a result, adhesion molecules, cytokines and chemokines, and a variety of other genes are being expressed that mediate and control the inflammatory process. In recent years, different classes of drugs have been developed that interfere with selected enzymes involved in the intracellular signalling cascades. In endothelial cell cultures, they exert potent inhibitory effects on the expression of genes, while several studies also report on in vivo effectiveness to confine the inflammatory responses. To prevent undesired toxicity and to improve drug behaviour and efficacy, drug carrier systems have been developed that selectively deliver the therapeutics into the activated endothelial cells. The above subjects are recapitulated to give an overview on the status of development of endothelial cell directed therapeutic strategies to pharmacologically interfere with chronic inflammatory diseases.
Keywords: endothelial cells, chronic inflammation, angiogenesis, signal transduction, drugs, pharmacology, vascular drug targeting
Current Vascular Pharmacology
Title: Molecular Pathways of Endothelial Cell Activation for (Targeted) Pharmacological Intervention of Chronic Inflammatory Diseases
Volume: 3 Issue: 1
Author(s): Joanna M. Kuldo, Ken Ichi Ogawara, Naomi Werner, Sigridur A. Asgeirsdottir, Jan A. A.M. Kamps, Robbert J. Kok and Grietje Molema
Affiliation:
Keywords: endothelial cells, chronic inflammation, angiogenesis, signal transduction, drugs, pharmacology, vascular drug targeting
Abstract: In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis factor α (TNFα), interleukin-1 (IL-1), vascular endothelial growth factor (VEGF), and fibroblast growth factors (FGFs). Receptor triggering initiates intracellular signal transduction leading to activation of nuclear factor κB (NFκB), mitogen activated protein kinase (MAPK) activity, and nitric oxide and reactive oxygen species production, among others. As a result, adhesion molecules, cytokines and chemokines, and a variety of other genes are being expressed that mediate and control the inflammatory process. In recent years, different classes of drugs have been developed that interfere with selected enzymes involved in the intracellular signalling cascades. In endothelial cell cultures, they exert potent inhibitory effects on the expression of genes, while several studies also report on in vivo effectiveness to confine the inflammatory responses. To prevent undesired toxicity and to improve drug behaviour and efficacy, drug carrier systems have been developed that selectively deliver the therapeutics into the activated endothelial cells. The above subjects are recapitulated to give an overview on the status of development of endothelial cell directed therapeutic strategies to pharmacologically interfere with chronic inflammatory diseases.
Export Options
About this article
Cite this article as:
Kuldo M. Joanna, Ogawara Ichi Ken, Werner Naomi, Asgeirsdottir A. Sigridur, Kamps A.M. Jan A., Kok J. Robbert and Molema Grietje, Molecular Pathways of Endothelial Cell Activation for (Targeted) Pharmacological Intervention of Chronic Inflammatory Diseases, Current Vascular Pharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570161052773898
DOI https://dx.doi.org/10.2174/1570161052773898 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Search for the Genetic Component of COPD: Role of the Clinical Phenotype
Current Respiratory Medicine Reviews Influence of Dietary Substances on Intestinal Drug Metabolism and Transport
Current Drug Metabolism Adjuvant Therapies of COVID-19 - A Literature Review
Coronaviruses Role of NLRP-3 Inflammasome in Hypertension: A Potential Therapeutic Target
Current Pharmaceutical Biotechnology Cerebrovascular Profile Assessment in Parkinson's Disease Patients
CNS & Neurological Disorders - Drug Targets Sildenafil Improves Vascular Endothelial Structure and Function in Renovascular Hypertension
Current Pharmaceutical Biotechnology Calixarene: A Versatile Material for Drug Design and Applications
Current Pharmaceutical Design An Umbrella Review of Nuts Intake and Risk of Cardiovascular Disease
Current Pharmaceutical Design Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Volatile and Semi-volatile Composition of the Ripe Brazilian Couroupita guianensis Fruit
The Natural Products Journal Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Microbial / Enzymatic Synthesis of Chiral Intermediates for Pharmaceuticals: Case Studies from BMS
Current Organic Chemistry Diagnosis and Management of Diabetes and the Relationship of dGlucose to Kidney Function
Current Diabetes Reviews Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews Clinical Perspectives on the Role of Anti-Platelet and Statin Therapy in Patients with Vascular Diseases
Current Vascular Pharmacology Impact of Short-Term Educational and Behavioral Therapy on Childhood Obesity
Vascular Disease Prevention (Discontinued) Structural Chromosome Abnormalities Associated with Obesity: Report of Four New Subjects and Review of Literature
Current Genomics Neurogenesis and Stroke
CNS & Neurological Disorders - Drug Targets Aqueous Humor Pharmacokinetics of Dorzolamide Loaded PLGAChitosan Nanoparticles by Ultra Performance Liquid Chromatography
Current Pharmaceutical Analysis Optimizing the Management of Uncontrolled Hypertension: What do Triple Fixed-Dose Drug Combinations Add?
Current Vascular Pharmacology